Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SORAYA: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer with High Folate Receptor-Alpha Expression
2020-000179-19Phase 3Completed
- Sponsor
- ImmunoGen
- Start
- Apr 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirvetuximab soravtansine in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 1 more, sponsored by ImmunoGen. Primary endpoint: Objective response rate. Started Apr 2020; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)malignant peritoneal neoplasm
Beyond the preview
Go deeper on 2020-000179-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000179-19.